Glaukos Corporation (GKOS) Tops Q1 EPS by 46c, Revenues Beat; Offers 2Q Revenues Guidance Above Consensus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. SWKS
7. ANET
8. SPY
9. XYZ
10. CVS

Go back to Glaukos Corporation (GKOS) Tops Q1 EPS by 46c, Revenues Beat; Offers 2Q Revenues Guidance Above Consensus

Glaukos Corporation Announces First Quarter 2021 Financial Results

May 5, 2021 4:10 PM EDT

SAN CLEMENTE, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the first quarter ended March 31, 2021. Key highlights include:

Net sales growth of 23% to $68.0 million in Q1 2021, compared to $55.3 million in Q1 2020. Glaucoma net sales of $53.7 million and Corneal Health net sales of $14.3 million in Q1 2021. Gross margin of approximately 76% and non-GAAP gross margin of approximately 84% in Q1 2021. Operating expenses of... More